Federal grants to New York University
New York University in Mineola, New York received $25.8 million in federal grants from fiscal 2021 to 2025, across 20 awards. Its largest program was Cardiovascular Diseases Research, with $14.4 million. In fiscal 2025 it was awarded $6.8 million.
From USAspending.gov award records, updated November 7, 2026.
- Grants, FY 2021 to 2025$25.8 million
- Awards20
- Awarded in FY 2025$6.8 million
- Largest award$7.4 million
By year
| Fiscal year | Awards | Amount |
|---|---|---|
| FY 2021 | 8 | $3.5 million |
| FY 2022 | 7 | $2.8 million |
| FY 2023 | 8 | $6.3 million |
| FY 2024 | 9 | $6.3 million |
| FY 2025 | 7 | $6.8 million |
Programs that fund New York University
| Program | Awards | Amount |
|---|---|---|
| Cardiovascular Diseases Research | 6 | $14.4 million |
| Diabetes, Digestive, and Kidney Diseases Extramural Research | 5 | $4.7 million |
| Assistance Programs for Chronic Disease Prevention and Control | 1 | $2.2 million |
| Child Health and Human Development Extramural Research | 2 | $1.7 million |
| Cooperative Agreements for Diabetes Control Programs | 2 | $1.1 million |
| Minority Health and Health Disparities Research | 1 | $698,001 |
| Military Medical Research and Development | 1 | $458,955 |
| Aging Research | 1 | $286,345 |
| 21st Century Cures Act - Precision Medicine Initiative | 1 | $146,720 |
Awarding agencies
| Agency | Awards | Amount |
|---|---|---|
| Department of Health and Human Services | 19 | $25.3 million |
| Department of Defense | 1 | $458,955 |
Largest awards
| Award | Program | First action | Amount |
|---|---|---|---|
| Biogenesis and catabolism of atherogenic lipoproteins - summary/abstract – overall: more people die of cardiovascular disease (CVD) than any other disease worldwide. Our proposal focuses on the biogenesis and catabolism of atherogenic apob- containing lipoproteins (apob-lps), which are major risk fa | Cardiovascular Diseases Research | April 28, 2023 | $7.4 million |
| Mapping mtp lipid transfer activities for better therapeutics - apolipoprotein-b (APOB)-containing lipoproteins are both a biomarker and a causal mediator of many central hallmarks of metabolic disease, including insulin resistance, fatty liver disease, atherosclerosis, obesity and metabolic syndrom | Cardiovascular Diseases Research | March 26, 2021 | $2.4 million |
| Role of ngbr in regulating hepatic gluconeogenesis and insulin resistance - project summary obesity-related type 2 diabetes (T2D) is the most common emerging metabolic disease in the us population. Insulin resistance is a key etiological factor of T2D. Adiponectin is an adipocyte-secreted hormone an | Diabetes, Digestive, and Kidney Diseases Extramural Research | March 23, 2022 | $2.3 million |
| Assessing the burden of diabetes by type in children, adolescents and young adults (DICAYA) - 2020 | Assistance Programs for Chronic Disease Prevention and Control | February 12, 2021 | $2.2 million |
| Regulation of plasma ldl and hdl by MICRORNA-541-3P - high ldl and low hdl levels are risk factors for cardiovascular disease. Our long-term goal is to identify and explain mechanisms through which micrornas (MIRS) regulate plasma lipoprotein levels. Here, we report the identification of a novel mir | Cardiovascular Diseases Research | June 1, 2023 | $1.9 million |
| Role of retinoid x receptor alpha in regulating PCSK9 transcription in the liver - project summary cardiovascular disease (CVD) still is the leading cause of death in the united states. The demand for novel treatments lead to the recent discovery of proprotein convertase subtilisin kexin 9 (PCSK9), | Diabetes, Digestive, and Kidney Diseases Extramural Research | March 2, 2023 | $1.8 million |
| Placenta-specific MIR-519C-MEDIATED induction of immune tolerance in human placenta | Child Health and Human Development Extramural Research | October 19, 2020 | $1.4 million |
| Reducing plasma cholesterol and atherosclerosis using MIR-30C analog C2 - title: reducing plasma cholesterol and atherosclerosis using MICRORNA-30C analog C2 abstract despite the many treatment advances that have emerged in the past 75 years, cardiovascular disease (CVD) remains a major cause of glo | Cardiovascular Diseases Research | September 23, 2025 | $1.4 million |
| BMAL1, a master regulator of macrophage cholesterol metabolism - multiple biochemical, physiological, and behavioral processes are at least partially governed by circadian rhythms. We have shown that global deficiencies in clock and BMAL1 increase atherosclerosis. In the past few years, two studies | Cardiovascular Diseases Research | March 8, 2024 | $1.1 million |
| Projecting the potential impact of mindfulness-based meditation on the risk of alzheimer's disease | Minority Health and Health Disparities Research | February 3, 2021 | $716,461 |
Questions people ask
How much federal grant money does New York University get?
$25.8 million in 20 grant awards from fiscal 2021 to 2025, as obligations reported to USAspending.gov.
Which agency gives New York University the most?
The Department of Health and Human Services, with $25.3 million in 19 awards. The Department of Defense follow.
What is New York University's largest federal grant?
$7.4 million under Cardiovascular Diseases Research, with its first action in the period on April 28, 2023. That counts only the money obligated in fiscal 2021 to 2025.
Which federal programs fund New York University?
Its largest are Cardiovascular Diseases Research, Diabetes, Digestive, and Kidney Diseases Extramural Research and Assistance Programs for Chronic Disease Prevention and Control.
Other grant recipients in Mineola
Largest federal grant recipients in New York · Federal grants in New York